Łukasz Januszkiewicz

Dr. Łukasz Januszkiewicz

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in EP Europace
Verified
Journal Article
Closed access
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
SBSérgio Barra
Sérgio Barra
RPRui Providencia
Rui Providencia
GCGiulio Conte
Giulio Conte
CACarlo de Asmundis
Carlo de Asmundis
SBSerge Boveda
Serge Boveda
Implantable cardioverter-defibrillator (ICD) may impact patients’ life significantly. The aim of this survey was to analyse the impact of the ICD on quality of life (QoL) metrics from the patient’s perspective. ‘Living with an ICD’ was a prospective, multicentre study with an online questionnaire submitted to the European Heart Rhythm Association (EHRA) Research Network centres as well as patient associations from 10 European countries; it was filled-in directly and personally by the patients that were invited to participate, with a minimal interaction or influence from the healthcare professionals. Overall, the questionnaire was completed by 1809 patients (624 women, 34.5%). Patients in their 60s and 70s and from Western Europe were the most represented. The median time from first ICD implantation was 5 years (IQR 2–10). Device-related complications were reported by 505 patients (22.4%), including one or more inappropriate shocks (n = 209, 11.6%). Almost half the respondents reported improved QoL, with a more favourable impact for those receiving cardiac resynchronization therapy-defibrillator (CRT-D), and only a 10th experienced a significant decrease in QoL. The occurrence of complications remained a major predictor of deteriorated QoL (odds ratio 2.1, 95% confidence interval 1.4–3.0, P < 0.001). In conclusion, most patients have a globally positive view and acceptance of ICD therapy, reporting preserved to improved QoL after device implantation. Complications, namely inappropriate shocks, affect the expectation of living a normal life post-implant and are associated with a significant decrease in QoL. Our findings also highlight the importance of a detailed informed consent process and the involvement of the patient in the decision-making process.

1 November 2015 in Heart Rhythm
Verified
Journal Article
Closed access
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
EVEszter Vegh
Eszter Vegh
RBRasmus Borgquist
Rasmus Borgquist
ABAbhishek Bose
Abhishek Bose
ASAjay Sharma
Ajay Sharma
KPKimberly A. Parks
Kimberly A. Parks

27 February 2018 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
PBPaweł Balsam
Paweł Balsam
PLPiotr Lodziński
Piotr Lodziński
ATAgata Tymińska
Agata Tymińska
Krzysztof OzierańskiKrzysztof Ozierański
Krzysztof Ozierański
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
MGMarcin Grabowski
Marcin Grabowski
Background: Today, the main challenge for researchers is to develop new technologies which may help to improve the diagnoses of cardiovascular disease (CVD), thereby reducing healthcare costs and improving the quality of life for patients. This study aims to show the utility of biomedical shirt-based electrocardiography (ECG) monitoring of patients with CVD in different clinical situations using the Nuubo® ECG (nECG) system. Methods: An investigator-initiated, multicentre, prospective observational study was carried out in a cardiology (adult and paediatric) and cardiac rehabilitation wards . ECG monitoring was used with the biomedical shirt in the following four independent groups of patients: 1) 30 patients after pulmonary vein isolation (PVI), 2) 30 cardiac resynchronization therapy (CRT) recipients, 3) 120 patients during cardiac rehabilitation after myocardial infarction, and 4) 40 pediatric patients with supraventricular tachycardia (SVT) before electrophysiology study. Approval for all study groups was obtained from the institutional review board. The biomedical shirt captures the electrocardiographic signal via textile electrodes integrated into a garment.The software allows the visualization and analysis of data such as ECG, heart rate, arrhythmia detecting algorithm and relative position of the body is captured by an electronic device. Discussion: The major advantages of the nECG system are continuous ECG monitoring during daily activities, high quality of ECG recordings, as well as assurance of a proper adherence due to adequate comfort while wearing the shirt. There are only a few studies that have examined wearable systems, especially in pediatric populations. Trial registration: This study is registered in ClinicalTrials.gov: Identifier NCT03068169. Background: Today, the main challenge for researchers is to develop new technologies which may help to improve the diagnoses of cardiovascular disease (CVD), thereby reducing healthcare costs and improving the quality of life for patients. This study aims to show the utility of biomedical shirt-based electrocardiography (ECG) monitoring of patients with CVD in different clinical situations using the Nuubo® ECG (nECG) system. Methods: An investigator-initiated, multicentre, prospective observational study was carried out in a cardiology (adult and paediatric) and cardiac rehabilitation wards . ECG monitoring was used with the biomedical shirt in the following four independent groups of patients: 1) 30 patients after pulmonary vein isolation (PVI), 2) 30 cardiac resynchronization therapy (CRT) recipients, 3) 120 patients during cardiac rehabilitation after myocardial infarction, and 4) 40 pediatric patients with supraventricular tachycardia (SVT) before electrophysiology study. Approval for all study groups was obtained from the institutional review board. The biomedical shirt captures the electrocardiographic signal via textile electrodes integrated into a garment.The software allows the visualization and analysis of data such as ECG, heart rate, arrhythmia detecting algorithm and relative position of the body is captured by an electronic device. Discussion: The major advantages of the nECG system are continuous ECG monitoring during daily activities, high quality of ECG recordings, as well as assurance of a proper adherence due to adequate comfort while wearing the shirt. There are only a few studies that have examined wearable systems, especially in pediatric populations. Trial registration: This study is registered in ClinicalTrials.gov: Identifier NCT03068169.

24 January 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
SBSérgio Barra
Sérgio Barra
EMEloi Marijon
Eloi Marijon
RPRui Providencia
Rui Providencia
Carlo de AsmundisCarlo de Asmundis
Carlo de Asmundis
SBSerge Boveda
Serge Boveda
Information provided to patients prior to implantable cardioverter-defibrillator (ICD) insertion and their participation in the decision-making process are crucial for understanding ICD function and accepting this lifelong therapy. The aim of this study is to evaluate the extent to which different aspects related to ICD and quality of life were transmitted to patients prior to ICD implantation. Prospective, multicenter European study with an online questionnaire initiated by the European Heart Rhythm Association. The questionnaire was filled-in directly and personally by the ICD patients who were invited to participate. A total of 1809 patients (majority in their 40s–70s, with 624 women, 34.5%) from 10 European countries participated in the study. The median time from first ICD implantation was 5 years (interquartile range 2–10). Overall, 1155 patients (71.5%) felt optimally informed at the time of device implantation, however many respondents received no information about ICD-related complications (n = 801, 49.6%), driving restrictions (n = 718, 44.5%), and possibility of end-of-life ICD deactivation (n = 408, 25.4%). Of note, women were less frequently involved in the decision-making process than men (47.3% vs. 55.9%, P = 0.003) and reported to be less often optimally informed before ICD implantation than men (61.2% vs. 76.8%, P < 0.001). More women mentioned the desire to have learned more about ICD therapy and the benefit/risk balance (45.4% vs. 33.7% of men; P < 0.001). This patient-based evaluation provides alarming findings on the lack of information provided to patients prior ICD implantation, particularly for women.

4 February 2017 in EP Europace
Verified
Journal Article
Closed access
EVEszter M Végh
Eszter M Végh
JKJagdesh Kandala
Jagdesh Kandala
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
JRJen Ren
Jen Ren
AMAlexandra Miller
Alexandra Miller
RBRasmus Borgquist
Rasmus Borgquist
Cardiac Resynchronization Therapy (CRT) reduces morbidity and mortality for patients with heart failure and wide QRS complex, but up to 1/3 of patients are "non-responders" to the therapy. This study examines the ability of a simple standard electrocardiogram (ECG)-based scoring system to predict clinical outcome. Four hundred and ninety-one consecutive patients with CRT-implants (79% males, mean age 71 years, LVEF 24%, 59% with ischemic cardiomyopathy, 83% in NYHA class III) were included from a single large volume centre. All patients met standard indications for CRT, and were followed for 3 years after CRT implantation. Three ECG parameters were measured on the post-implant ECG, and compared to pre-implantation measurements: QRS duration, time to intrinsicoid deflection onset (ID) in V1 lead, amplitude change in V1 lead. Each positive ECG variable was given a numerical value of 1 to create the score (ranging 0-3). Clinical outcome was assessed as a composite of all-cause death, left ventricular assist device implantation, cardiac transplantation and HF hospitalization. Event-free survival was predicted by shortening of QRS duration ≥20 ms (HR 0.66 [95% CI 0.48-0.90] P = 0.009), ≥50% decreased summed R + S amplitude in V1 lead (HR 0.67 [0.49-0.90] P = 0.009) and ≤40 msec ID time in lead V1 during pacing (HR 0.63 [0.46-0.86] P = 0.004). The total score was an independent predictor for both event-free survival (HR 0.65 [0.54-0.77] P < 0.001) and for ≥10% left ventricular ejection fraction improvement (OR 1.7 [1.3-2.3] P < 0.001). Composite data from 12-lead ECG during CRT-treatment can be used in a simple score to predict long-term clinical outcome.

4 July 2013 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
ŁJŁukasz Januszkiewicz
Łukasz Januszkiewicz
ESEwa Szczerba
Ewa Szczerba
PPPaulina Paszkowska
Paulina Paszkowska
ACAndrzej Cacko
Andrzej Cacko
MGMarcin Grabowski
Marcin Grabowski
GOGrzegorz Opolski
Grzegorz Opolski
Multiple factors that affect the prognosis of acute coronary syndromes (ACS) have been identified. There are scarce data on the effect of the blood group on prognosis in this patient group. We investigated the effect of ABO and Rh (D antigen) status on the prognosis of ACS. A group of 418 consecutive hospitalized patients with ACS were analyzed. The follow‑up period was 2075 ±794 days. The primary endpoint was all‑cause mortality. A statistical analysis was performed for the following subgroups: ABO blood group, ABO blood group including Rhesus (Rh) factor (D antigen), Rh‑positive vs. Rh‑negative blood group, O blood group vs. non‑0 blood group, blood group with vs. without the B antigen, and blood group with vs. without the A antigen. A total of 348 patients (83.25%) were Rh-positive, while 70 (16.75%) were Rh‑negative. The Kaplan-Meier survival plots showed 7‑year mortality of 22.7% in patients with blood groups with Rh antigen and of 10% in patients without Rh antigen (P = 0.014). Other comparisons were not statistically significant. A multivariable Cox proportional hazards model identified blood group with D antigen as an independent predictor of mortality (hazard ratio, 7.758; 95% confidence interval, 1.748-34.417; P = 0.007). Of all blood groups, only the Rh‑positive blood group was an independent predictor of mortality in patients with ACS.